Velbe: Uses, Dosage & Side Effects

What Is Velbe and What Is It Used For?

Velbe contains the active substance vinblastine sulfate, a naturally occurring alkaloid originally isolated from the Madagascar periwinkle plant (Catharanthus roseus, formerly known as Vinca rosea). The discovery of vinblastine in the late 1950s was a landmark event in cancer pharmacology, as it was one of the first plant-derived compounds shown to have significant anticancer activity. Along with vincristine (a closely related vinca alkaloid), vinblastine opened an entirely new chapter in the treatment of hematological malignancies and solid tumors.

Vinblastine is classified as a cytotoxic agent, meaning it is toxic to cells – particularly those that are actively growing and dividing. The drug exerts its primary anticancer effect by binding to tubulin, a structural protein that is essential for the formation of microtubules. Microtubules are critical components of the mitotic spindle, the cellular machinery that separates chromosomes during cell division. By preventing the assembly of microtubules, vinblastine arrests cells in metaphase (a critical stage of cell division), ultimately leading to cell death through apoptosis. Because cancer cells typically divide more rapidly than most normal cells, they are preferentially affected by this mechanism.

In addition to its effects on the mitotic spindle, vinblastine also interferes with other microtubule-dependent cellular processes, including intracellular transport, cell signaling, and maintenance of cell shape. These pleiotropic effects may contribute to its overall anticancer activity. The drug also has some immunosuppressive properties, as it can affect the function and proliferation of immune cells, particularly lymphocytes.

Vinblastine is used in the treatment of a wide range of cancers, either as a single agent or more commonly as part of combination chemotherapy regimens. Its major therapeutic indications include:

• Hodgkin lymphoma: Vinblastine is a key component of the ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine), which has been the gold standard first-line treatment for Hodgkin lymphoma for decades. ABVD has cure rates exceeding 80% for early-stage disease and 60–70% for advanced-stage disease. Vinblastine is also used in the MOPP/ABV hybrid regimen and other combination protocols.
• Testicular germ cell tumors: Vinblastine has been used in combination regimens for the treatment of metastatic testicular cancer, including the PVB protocol (cisplatin, vinblastine, bleomycin), which was one of the first curative chemotherapy regimens for advanced testicular cancer before being largely replaced by BEP (bleomycin, etoposide, cisplatin).
• Bladder cancer: Vinblastine is a component of the MVAC regimen (methotrexate, vinblastine, doxorubicin, cisplatin), which has been a standard treatment for advanced or metastatic urothelial (bladder) cancer.
• Non-small cell lung cancer: Vinblastine is used in some combination regimens for the treatment of advanced non-small cell lung cancer, particularly in combination with cisplatin.
• Breast cancer: Vinblastine may be used as part of combination chemotherapy for advanced breast cancer, although it is less commonly used in current practice compared with other agents.
• Kaposi sarcoma: Vinblastine has activity against Kaposi sarcoma and is used both systemically and as an intralesional injection for cutaneous disease.
• Other cancers: Vinblastine has also been used in the treatment of histiocytosis (Langerhans cell histiocytosis), choriocarcinoma, renal cell carcinoma, and certain other solid tumors and hematological malignancies.

Vinblastine is included on the World Health Organization (WHO) Model List of Essential Medicines, underscoring its importance in cancer treatment worldwide. Despite the development of many newer anticancer agents, vinblastine remains an indispensable drug in oncology due to its proven efficacy, well-characterized safety profile, and relatively low cost compared with modern targeted therapies and immunotherapies.

What Should You Know Before Receiving Velbe?

Before starting treatment with Velbe, your doctor will conduct a thorough medical evaluation. It is essential that your healthcare team has a complete picture of your medical history, current medications, and overall health status to ensure the safest and most effective use of this cytotoxic drug. Several conditions and circumstances require special attention or may prevent you from receiving vinblastine.

Contraindications

There are specific situations in which Velbe must not be administered. These absolute contraindications exist because the risks of treatment would clearly outweigh any potential benefits:

• Hypersensitivity: Do not receive Velbe if you are allergic to vinblastine sulfate or any of the other ingredients in the product (sodium hydroxide and sulfuric acid used for pH adjustment). Although allergic reactions to vinblastine are uncommon, any previous hypersensitivity to vinca alkaloids should be reported to your doctor.
• Active bacterial infection: Velbe must not be given if you have an untreated bacterial infection that requires treatment first. Because vinblastine suppresses the immune system (particularly white blood cells), administering it during an active infection could lead to overwhelming sepsis and potentially fatal outcomes. The infection must be adequately controlled before chemotherapy can begin.
• Severe leukopenia not due to the disease being treated: If your white blood cell count is already very low for reasons other than the cancer being treated, vinblastine should not be given, as it would further suppress bone marrow function and increase the risk of life-threatening infections. However, if the low white blood cell count is caused by the underlying malignancy (such as bone marrow infiltration by lymphoma), treatment may still be considered under careful supervision.

Warnings and Precautions

Talk to your doctor or nurse before receiving Velbe if any of the following conditions apply to you:

• Ischemic heart disease: If you have coronary artery disease, angina, or a history of heart attacks, inform your doctor. Vinblastine may have cardiovascular effects, particularly when used in combination with other chemotherapy agents such as cisplatin and bleomycin, which have been associated with myocardial infarction and peripheral vascular events (Raynaud’s phenomenon).
• Liver impairment: Vinblastine is primarily metabolized in the liver. If you have reduced liver function (hepatic impairment), the drug may accumulate in your body, leading to increased toxicity. Your doctor may need to reduce the dose or monitor you more closely. Patients with significant liver disease (especially those with direct bilirubin levels exceeding 3 mg/dL) may require substantial dose reductions.
• Bone marrow function: Vinblastine causes bone marrow suppression, with leukopenia (low white blood cell count) being the primary dose-limiting toxicity. Your blood counts will be monitored before each treatment cycle. If your white blood cell count drops too low, treatment may need to be delayed until your counts recover.
• Extravasation risk: If vinblastine leaks out of the vein during injection (extravasation), it causes severe local tissue irritation and potential tissue damage. The injection must be stopped immediately, any remaining drug should be administered through a different vein, and local warmth should be applied to disperse the leaked medication. Healthcare professionals administering vinblastine must use meticulous injection technique and monitor the injection site carefully.

Pregnancy and Breastfeeding

Velbe is not recommended during pregnancy. As a cytotoxic drug that interferes with cell division, vinblastine has the potential to cause serious harm to a developing fetus, including birth defects and fetal death. Animal studies and the known mechanism of action strongly suggest teratogenic potential. Women who are pregnant or planning to become pregnant should not receive vinblastine unless the potential benefit clearly justifies the risk to the fetus, and only after thorough discussion with a specialist oncologist.

Breastfeeding is not recommended during treatment with vinblastine. It is not known with certainty whether vinblastine is excreted in human breast milk, but given its cytotoxic properties, a risk to the breastfed infant cannot be excluded. Women should discontinue breastfeeding before starting treatment.

Both male and female patients of reproductive potential should use effective contraception during treatment with vinblastine. Men should be aware that vinblastine can affect sperm production, and azoospermia (absence of sperm) has been reported, particularly when vinblastine is used in combination with other chemotherapy agents. Amenorrhea (absence of menstrual periods) has also been reported in women. Fertility preservation options, such as sperm banking for men and egg or embryo freezing for women, should be discussed with your doctor before starting chemotherapy.

Driving and Operating Machinery

Some side effects of Velbe may affect your ability to drive or operate machinery safely. These include fatigue, dizziness, headache, and neurological effects such as numbness or tingling in the extremities. Do not drive or use machines until you know how vinblastine treatment affects you. You are responsible for assessing whether you are fit to perform these activities. Discuss any concerns with your doctor.

Important Information About Ingredients

Velbe contains less than 1 mmol (23 mg) of sodium per vial, meaning it is essentially sodium-free. This is relevant for patients on sodium-restricted diets. The other excipients are sodium hydroxide and sulfuric acid, which are used to adjust the pH of the reconstituted solution.

How Does Velbe Interact with Other Drugs?

Drug interactions with vinblastine can occur through several mechanisms. Vinblastine is metabolized primarily in the liver by the cytochrome P450 CYP3A subfamily, so drugs that inhibit or induce these enzymes can affect vinblastine levels in the body. Additionally, when vinblastine is used in combination with other anticancer drugs (as is standard practice), the overlapping toxicity profiles of the different agents must be carefully managed. It is essential to tell your doctor about all medications, supplements, and herbal products you are taking.

Major Interactions

Minor Interactions

Vinblastine is commonly used as part of multi-drug chemotherapy regimens where these drug interactions are anticipated and managed by experienced oncologists. The ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine) for Hodgkin lymphoma and the MVAC regimen (methotrexate, vinblastine, doxorubicin, cisplatin) for bladder cancer are examples of well-established combinations where the overlapping toxicities of the individual drugs have been thoroughly studied and managed through decades of clinical experience.

Always inform your oncology team about all prescription and non-prescription medications, herbal supplements, and vitamins you are taking, as unexpected interactions may occur. This is particularly important with herbal products such as St. John’s wort, which is a potent CYP3A4 inducer and may reduce vinblastine efficacy.

What Is the Correct Dosage of Velbe?

Velbe is a cytotoxic drug that must be prepared and administered exclusively by healthcare professionals experienced in handling and administering chemotherapy agents. The dose is calculated individually for each patient based on the specific treatment protocol being followed, the patient’s body surface area (BSA, calculated from height and weight), blood count results, and overall clinical condition. Dose modifications are common based on how the patient responds to treatment and whether side effects, particularly bone marrow suppression, are within acceptable limits.

Preparation and Administration

Velbe is supplied as a white to almost white powder in a vial containing 10 mg of vinblastine sulfate. Before administration, the powder must be reconstituted by adding 10 mL of sterile sodium chloride 0.9% solution (normal saline) or sterile water for injection. The solvent should be added slowly along the wall of the vial to avoid dispersing the active substance into the environment. The reconstituted solution is clear and colorless, with a concentration of 1 mg/mL and a pH of 4–5.

Vinblastine is administered by direct intravenous injection (bolus) over approximately 1 minute, either via a multi-way stopcock during an ongoing intravenous infusion of normal saline or via a free-flowing IV line. Meticulous injection technique is essential to prevent extravasation (leakage outside the vein), which causes severe tissue damage.

Adults

Children

The use of vinblastine in pediatric patients is determined by the specific treatment protocol and the child’s condition. Vinblastine is used in children primarily for the treatment of Hodgkin lymphoma and Langerhans cell histiocytosis. Dosing in children is based on body surface area and follows established pediatric oncology protocols. All pediatric chemotherapy must be administered in specialized centers with expertise in childhood cancer treatment.

Dose Modifications

Dose adjustments are frequently required based on the patient’s response to treatment and the severity of side effects. The primary dose-limiting toxicity is leukopenia (low white blood cell count). Your doctor will check your blood counts before each treatment cycle and may delay treatment or reduce the dose if your white blood cell count is too low. For patients with hepatic (liver) impairment, dose reduction is recommended, particularly when direct bilirubin exceeds 3 mg/dL, as impaired liver function can lead to significantly increased drug exposure and toxicity.

Overdose

Overdose with vinblastine can lead to exaggerated side effects, particularly severe bone marrow suppression, which may be life-threatening. There is no specific antidote for vinblastine overdose. Treatment is supportive and symptomatic, focusing on managing bone marrow suppression (with growth factor support and blood transfusions as needed), preventing and treating infections, and providing supportive care for other toxicities. In case of suspected overdose, immediate medical attention is essential.

What Are the Side Effects of Velbe?

Like all cytotoxic chemotherapy drugs, Velbe can cause side effects, although not everyone who receives it will experience them. The severity of side effects is closely related to the dose administered. The most significant and dose-limiting side effect is bone marrow suppression, particularly leukopenia (low white blood cell count), which increases the risk of infections. Your healthcare team will monitor you closely throughout treatment and take appropriate measures to manage any side effects that develop.

The following side effects have been observed during treatment with vinblastine. They are organized by frequency according to international medical conventions:

The bone marrow suppression caused by vinblastine typically reaches its lowest point (nadir) 5–10 days after administration, with recovery usually occurring within 7–14 days. During the nadir period, patients are at their highest risk for infections and bleeding. Your doctor will schedule blood tests to monitor your blood cell counts at appropriate intervals and may adjust the timing or dose of your next treatment based on the results.

Neurological side effects of vinblastine are generally less common and less severe than those seen with vincristine (a related vinca alkaloid). However, when neurological effects do occur, they may persist for longer than 24 hours, unlike most other side effects of vinblastine. Peripheral neuropathy (numbness, tingling, or pain in the hands and feet) and loss of deep tendon reflexes can occur, particularly at higher doses or with prolonged treatment.

If you experience any side effects, including any not listed above, talk to your doctor, pharmacist, or nurse. Reporting suspected adverse reactions after a medicine has been authorized is important as it allows ongoing monitoring of the benefit-risk balance of the medicine.

How Should Velbe Be Stored?

Proper storage of Velbe is essential to maintain its stability and efficacy. The unreconstituted powder must be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). Keep the vial in its original packaging to protect it from light. Do not freeze.

After reconstitution with 10 mL of sterile sodium chloride 0.9% solution or sterile water for injection, the solution should be stored in the refrigerator (2°C–8°C) and must be used within 24 hours. The reconstituted solution should be inspected visually for particulate matter and discoloration before administration. It should appear as a clear, colorless solution. Do not use the solution if it is cloudy, discolored, or contains visible particles.

Keep Velbe out of the sight and reach of children. As a cytotoxic agent, any unused product or waste material (including vials, swabs, syringes, and other items that have come into contact with the solution) must be disposed of in accordance with local regulations for hazardous pharmaceutical waste. Do not discard vinblastine in household waste or drain.

What Does Velbe Contain?

Understanding the composition of your medication is important for identifying potential allergens and ensuring proper handling. Velbe has a straightforward formulation with minimal excipients:

• Active substance: Vinblastine sulfate 10 mg per vial. Vinblastine sulfate is the sulfate salt form of vinblastine, a naturally occurring alkaloid derived from the periwinkle plant (Catharanthus roseus).
• Other ingredients (excipients): Sodium hydroxide and sulfuric acid. These are used solely to adjust the pH of the reconstituted solution to the optimal range of 4–5 for stability and compatibility with intravenous administration.

Velbe is an almost white powder. Each package contains one vial of powder for solution for injection (1 × 10 mg). After reconstitution with 10 mL of diluent, the resulting solution has a concentration of 1 mg/mL.

The solution must not be mixed with other medications and should not be diluted with injection solutions that alter the pH, as this may affect the stability of vinblastine. Compatibility should be verified before mixing with any intravenous solution other than the recommended diluents (sterile 0.9% sodium chloride solution or sterile water for injection).